Gennady Landa, MD, is vice chair, clinical integration of ophthalmology, Mount Sinai Health System; director of retina service, NYEEI; and associate professor of ophthalmology, vitreoretinal surgeon ...
Recapping a recent conversation led by Dilsher S. Dhoot, MD. In May 2025, Dilsher S. Dhoot, MD, moderated a Case-Based Roundtable® that brought together practicing retina specialists and residents ...
Manufacturers are stepping up to design products that will help maximize the safety and efficiency of intravitreal injection. The ideal syringe for administering intravitreal injections does not exist ...
The trial evaluated nesvategrast (OTT166 5%) eye drops in patients with diabetic retinopathy. OcuTerra announced topline results from its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) ...
Altris also has advanced AI models to enable vendor-neutral retina layers segmentation as well as detection and visualization of more than 70 retina conditions such as dry and wet age-related macular ...
The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation. Today Nanoscope Therapeutics announced its ...
An expert demonstrates how to safely co-manage AMD and GA using staggered dual-pathway treatment to maintain stability and patient confidence. Dr. Sambhara presents an 87-year-old male with geographic ...
Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao highlight gene therapy as a future treatment of neovascular AMD and DME and how it will significantly reduce the burden on patients.
Curacle plans to finalize its development strategy, including phase 2b and 3 trials, through a Type C meeting with the US FDA in February of 2025. Curacle presented the results of its phase 2a ...
These continued studies also demonstrate a well-tolerated safety profile in a broad population of more than 1,200 patients. Results from the phase 3 OAKS and DERBY studies evaluating pegcetacoplan ...
EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD. EyePoint Pharmaceuticals recently announced the completion of ...
Adrienne Scott, MD, and Prethy Rao, MD, MPH, discuss implementation of step therapy in neovascular age-related macular degeneration and diabetic macular edema without compromising vision outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results